Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Feb
16
Today In Oncology
Induction Nivolumab Before CRT in High-Risk HPV-Driven OPC
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive Breast Cancer
Nonmetastatic Breast Cancer Treatment Strategies After Denosumab Discontinuation in Patients Treated With Aromatase Inhibitors
ASH Guidelines on Management of Newly Diagnosed and Relapsed/Refractory ALL in AYA Patients
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo